
‘Designer Xanax’ behind rising number of overdose deaths: CDC report
NY Post
A new report from the Centers for Disease Control and Prevention is raising concerns over so-called “designer Xanax” that has been tied to a rising number of deaths and hospitalizations.
The drug, an unapproved benzodiazepine (“benzos”) sedative called bromazolam, has led to hyperthermia, seizures, myocardial injury, comas and multi-day intensive care stays, according to CDC data.
Bromazolam — also known by street names like “fake Xanax” and “dope” — is one of at least a dozen unapproved “designer” benzodiazepines, a class of drugs used to treat anxiety, that has been created in the lab to be more potent than approved drugs.
The CDC’s Morbidity and Mortality Weekly Report (MMWR) detailed three case studies of “previously healthy young adults” — two 25-year-old men and one 20-year-old woman — who took bromazolam thinking it was alprazolam (Xanax).
In February 2023, the three 20-somethings were found unresponsive after taking the disguised drug and couldn’t be revived with alprazolam, an opioid reversal agent. They were still unresponsive upon arrival at the emergency unit.
All three experienced multiple generalized seizures and her intubated while in the ICU to help maintain their breathing. They also had fevers and showed signs of heart damage.
